For much of Foundayo’s development, one of the biggest questions around the drug was whether the liver would become a problem.

That concern was not contrived for clicks. Small-molecule (non-peptide) oral GLP-1 drugs had already produced enough liver-related trouble elsewhere in the field to make this industry observer… Cautious. Pfizer discontinued lotig…